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Cell Background: Respiratory syncytial virus (RSV) is a major
health care burden with a particularly high worldwide
morbidity and mortality rate among infants. Data suggest that
severe RSV-associated illness is in part caused by
immunopathology associated with a robust type 2 response.
Objective: We sought to determine the capacity of RSV
infection to stimulate group 2 innate lymphoid cells (ILC2s) and
the associated mechanism in a murine model.
Methods: Wild-type (WT) BALB/c, thymic stromal
lymphopoietin receptor (TSLPR) knockout (KO), or WT mice
receiving an anti-TSLP neutralizing antibody were infected with
the RSV strain 01/2-20. During the first 4 to 6 days of infection,
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Results were confirmed with 2 additional RSV clinical isolates,
12/11-19 and 12/12-6, with known human pathogenic potential.
Results: RSV induced a 3-fold increase in the number of
IL-13–producing ILC2s at day 4 after infection,with a concurrent
increase in total lung IL-13 levels. Both thymic stromal
lymphopoietin (TSLP) and IL-33 levels were increased 12 hours
after infection. TSLPR KO mice did not mount an IL-13–
producing ILC2 response to RSV infection. Additionally,
neutralization of TSLP significantly attenuated the RSV-induced
IL-13–producing ILC2 response. TSLPR KO mice displayed
reduced lung IL-13 protein levels, decreased airway mucus and
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producing ILC2s through a TSLP-dependent mechanism.
Conclusion: These data demonstrate that multiple pathogenic
strains of RSV induce IL-13–producing ILC2 proliferation and
activation throughaTSLP-dependentmechanisminamurinemodel
and suggest the potential therapeutic targeting of TSLP during
severe RSV infection. (J Allergy Clin Immunol 2016;138:814-24.)
Keywords: Group2 innate lymphoid cells, IL-13, IL-33, thymic stromal
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Respiratory syncytial virus (RSV) is the leading cause of infant
hospitalization in the United States.1 RSV induces bronchiolitis
and viral pneumonia and can lead to death in severe cases. Current
therapeutic options are limited. Ribavirin, a nucleoside analog
that inhibits viral replication, has shown poor effectiveness in
treating RSV-induced disease.2 Corticosteroids have also proved
ineffective during virus-induced bronchiolitis, failing to reduce
the number of hospital admissions, length of stay, or disease
severity.3-5 The majority of treatment strategies are supportive,
focusing on fluid and respiratory maintenance. Widely available
and cost-effective preventative options are also lacking. The
only US Food and Drug Administration–approved preventative
therapy is palivizumab, an antibody directed against the surface-
exposed RSV fusion protein, which, when given as prophylaxis,
decreases the number of RSV-associated hospitalizations by up
to 55%.6,7 Although effective, palivizumab is prohibitively
expensive for widespread use and is currently only recommended
for infants in the first year of life with chronic lung disease, with
hemodynamically significant congenital heart disease, or born
significantly premature (<29 weeks).8 Moreover, decades of
research have failed to yield a safe and effective RSV vaccine.
Our incomplete understanding of the immune response to RSV
presents a major obstacle to the development of new therapeutics
and a vaccine. It is unclear which aspects of the immune response
are protective and which are detrimental. Severe RSV infection in
infants is characterized by airway epithelial cell destruction and
sloughing, mucus production, peribronchiolar inflammation, and
pulmonary obstruction.9 Classically, mucus production has been
associated with activation of CD41 TH2 cells.
10 CD41 TH2 cells
mediate responses to certain viral, parasitic, bacterial, and
allergen exposures and produce the cytokine IL-13, a central
mediator of airway reactivity and mucus production.11 However,
no studies have evaluated early IL-13 production during RSV
infection before CD41 TH2 cell maturation. A better understand-
ing of the host immune response to RSV will inform rational
design of new clinical and pharmacologic interventions.
Group 2 innate lymphoid cells (ILC2s) are an early and significant
source of IL-13 in several other pulmonary diseases.12-21 ILC2s are
temporally and functionally distinct from TH2 cells. Unlike T and
B cells, ILC2s do not have specific antigen receptors.
Rather, ILC2s act primarily as early innate effector cells that
respond directly to cytokine stimulation.22-24 Specifically, the
epithelium-associated cytokines IL-25, IL-33, and thymic stromal
lymphopoietin (TSLP) induce ILC2 proliferation and activa-
tion.12,22-24 Lung-resident ILC2s express high levels of IL-5 and
IL-13 but minimal IL-4.25 This is in contrast to mature effector
TH2cells,whichexpress all 3 cytokines.Comparatively, early reports
suggest that ILC2s are significantlymore potent thanTH2 cells, elab-
orating greater than 10 times the amount of TH2 cytokines on a per-
cell basis.25 Our understanding of lung ILC2s has largely come frominvestigations into their role in patients with allergic asthma, where
they have been characterized as important mediators of airway
responsiveness, eosinophilia, and mucus production.12,14,18-20
Several studies have also shown that ILC2s can play a role in patho-
logic changes during influenza and rhinovirus infections through
either IL-33 or IL-25, although the effect of TSLP on virus-
induced ILC2 activation in the lungs remains unknown.15-17,21,26
We hypothesized that RSV induces a robust IL-13–producing
ILC2 response during the early phase of RSV infection in a
murine model. To test this hypothesis, we used the RSV clinical
strain 01/2-20, which was isolated from a patient with
RSV-induced bronchiolitis and potentiated IL-13 production in
mice.27 We identified a significant increase in the total lung IL-13
concentration and the number of IL-131 ILC2s at day 4 after
infection. TSLP signaling was required for this ILC2
enhancement. Moreover, RSV-infected thymic stromal
lymphopoietin receptor (TSLPR)–deficient mice had reduced
lung IL-13 protein concentration and decreased airway mucus
and reactivity, were partially protected from RSV-induced weight
loss, and had comparable viral loads to wild-type (WT) mice.
Finally, infection of mice with recent clinical isolates of RSV
with known human pathogenic potential demonstrated a similar
induction of IL-131 ILC2s at day 4 after infection that required
TSLP. Collectively, these data demonstrate a critical role for
TSLP in RSV-induced ILC2 activation, suggesting this cytokine
as a potential therapeutic target to treat the immune-associated
pathology of severe RSV-associated illness.METHODS
Full methods are available in the Methods section in this article’s Online
Repository at www.jacionline.org; a brief summary is provided here.
Viruses and mice
RSV strains 01/2-20,27 which was isolated from a patient in 2001 in the
Vanderbilt Vaccine Clinic, and 12/11-19 and 12/12-6,28 which were isolated
in 2012 from hospitalized patients with RSV-induced lower respiratory tract
infection as part of the Infant Susceptibility to Pulmonary Infections and
Asthma Following RSV Exposure (INSPIRE) study, were propagated and
titrated in HEp-2 cells, as previously described.29 Female 8- to 12-week-old
IL-33 citrine reporter (IL-33-deficient; IL-33 knockout [KO]) mice,
TSLPR-deficient (TSLPR KO) mice, or WT BALB/c mice were purchased
from the Jackson Laboratory (Bar Harbor, Me). Mice were housed in
microisolator cages under specific pathogen-free conditions. For infection,
mice were anesthetized with a ketamine/xylazine solution and inoculated by
J ALLERGY CLIN IMMUNOL
SEPTEMBER 2016
816 STIER ET ALmeans of intranasal delivery of 3.03 106 plaque-forming units (PFU) of RSV
01/2-20, 1.03 106 PFU of RSV 12/11-19, 9.03 105 PFU of RSV 12/12-6, or
an equal volume of mock inoculum, as previously described.29ELISA
Protein measurements for IL-25, IL-33, TSLP, IL-4, IL-5, and IL-13 (R&D
Systems, Minneapolis, Minn) were performed on frozen and mechanically
disrupted lungs, according to the manufacturer’s instructions.
Flow cytometry
Lungs were digested in RPMI media with 5% FBS, 1 mg/mL collagenase,
and 0.02 mg/mL DNase I for 60 minutes at 378C. A single-cell suspension was
generated by straining these digestions through a 70-mm filter. RBC
lysis (BioLegend, San Diego, Calif) was performed, according to the
manufacturer’s instructions. Cells were restimulated with 10 ng/mL phorbol
12-myristate 13-acetate and 1 mmol/L ionomycin in the presence of 0.07%
monensin in Iscove modified Dulbecco medium supplemented with 10%
FBS, 0.01 mmol/L nonessential amino acids, penicillin/streptomycin, and
1 mmol/L sodium pyruvate for 6 hours at 378C. Cells were stained for viability
and cell-surface proteins, fixed/permeabilized, and stained for intracellular
antigens. All samples were run on a BD LSR II Flow Cytometer (BD
Biosciences, San Jose, Calif) and analyzed with FlowJo software (Version 10;
FlowJo, Ashland, Ore). Total innate lymphoid cells (ILCs) were defined as
Lin2CD451CD251CD1271 cells, where Lin includes CD3, CD5, CD45R
(B220), CD11b, Gr-1 (Ly-6G/C), 7-4, and Ter-119. ILC2s were defined as
ILCs that expressed IL-5, IL-13, or both. T cells were defined as CD451CD31
cells.Meanfluorescence intensity (MFI)was determined as the geometricmean.
In vivo TSLP neutralization
At either 6 or 36 hours after RSV infection, mice received a single dose of
200 mg of 28F12, an anti-TSLP mAb with established in vivo neutralizing
capacity,30-32 or isotype control antibody through intraperitoneal injection.
Periodic acid–Schiff staining
Lungs were fixed in 10% neutral buffered formalin. Fixed lungs were
paraffin embedded, sectioned (5 mm), and stained with periodic acid–Schiff
(PAS) to visualize mucus, as previously described.33 Small- and
medium-sized airways were scored for mucus by a trained pathologist blind
to the experimental information.
Airway reactivity
Airway reactivity was measured, as previously described.34,35
Statistical analysis
Data were analyzed with GraphPad Prism software (version 5; GraphPad
Software, La Jolla, Calif). Differences between groups were evaluated by
using the unpaired t test, 1-wayANOVAwith the Bonferroni posttest, or 2-way
ANOVA with the Dunn multiple comparison test, as appropriate.
Measurements of less than the limit of detection were assigned half of the
value of the limit of detection to allow for statistical analyses.RESULTS
RSV infection increases the concentration of IL-13
and the number of IL-13–producing ILC2s in the
lungs at day 4 after infection
We first determined the kinetics of IL-13 expression in the lungs
of RSV-infected mice. Eight-week-old WT mice were infected
with 33 106 PFU of RSV clinical isolate 01/2-20, and lungs were
harvested on days 0, 2, 4, 6, 8, and 10 formeasurement of IL-13 by
using ELISA. Therewas a significant induction of IL-13 protein inthe lungs of RSV-infected mice compared with levels seen in
mock-infected mice beginning at day 4 after infection and
continuing through day 8 after infection (Fig 1, A). We hypothe-
sized that ILC2s rather than T cells were the predominant source
of the early IL-13 observed at day 4 after infection because this
time point precedes the adaptive immune response during RSV
infection.36 No unique surface markers are presently known to
identify ILC2s exclusively.Wedefined ILCs as hematopoietic line-
age marker (CD3, CD5, B220, CD11b, Gr-1, 7-4, and Ter-119)–
negative CD451, CD251, and CD1271 and ILC2s as ILCs that
are IL-51, IL-131, or both by using flow cytometry (see Fig E1
in this article’s Online Repository at www.jacionline.org).37 At
day 4 after infection, we noted a significant increase in the total
number of cells in the lung, the percentage of live cells that were
ILCs and IL-131 ILC2s, and the total number of ILCs and
IL-131 ILC2s in RSV-infected mice relative to mock-infected
mice (Fig 1, B-E and G-H). Moreover, viral replication was
required for this phenomenon because inoculation with
UV-inactivated virus did not increase the number of ILCs or
IL-131 ILC2s compared with mock inoculum (Fig 1, B-E and
G-H). Additionally, the ILC compartment had an increased
side-scatter MFI, which is consistent with an activate state
(Fig 1, F).18,38 Finally, the MFI of IL-13 in ILC2s was higher in
the RSV-infected group compared with that seen after inoculation
with mock preparation or UV-inactivated virus, suggesting
increased production of IL-13 on a per-ILC2basis after RSVinfec-
tion (Fig 1, I). As expected at day 4 after infection, IL-131 T cells
were not detected because staining for IL-13 in the CD31 T-cell
compartment was comparable with isotype signal (Fig 1, B).
ILC2s also have the potential to express considerable amounts
of IL-5 in addition to IL-13. We did not identify appreciable
concentrations of IL-4 or IL-5 by using ELISA in RSV-infected
mice compared with mock-infected mice during the first 10 days
after RSV infection, with only IL-4 concentrations being
statistically significant but just slightly greater than the limit of
detection at day 6 after infection (see Fig E2, A and B, in this
article’s Online Repository at www.jacionline.org). Consistent
with this finding, we did not identify a significant difference in
the total number of IL-51 ILC2s or in MFI of IL-5 at day 4 after
infection between mock- and RSV-infected mice (see Fig E2,
C-F). Furthermore, RSV infection did not increase the percentage
or total number of eosinophils in bronchoalveolar lavage (BAL)
fluid at day 4 after infection compared with values in
mock-infected mice (see Fig E2, G-H). These data suggest that
the predominant functional capacity of ILC2s induced during
RSV infection is the expression of IL-13.
Moreover, there was a significant increase in the number of
total ILCs and IL-131 ILC2s that stained for Ki67, a marker of
cellular proliferation, at day 4 after infection in the RSV-
infected group compared with the mock-infected group (Fig 2).
These data suggest that local proliferation of ILC2s within the
lungs contributes to the increase in the total number of ILCs
and IL-131 ILC2s as a result of RSV infection. Collectively, these
data suggest that ILC2s are a source of early IL-13 production
after RSV infection.TSLP is necessary for the RSV-induced ILC2
response
We next sought to understand the mechanism by which RSV
drives ILC2 accumulation in the lungs. TSLP has not previously
FIG 1. RSV infection induced whole-lung IL-13 accumulation and IL-13–producing ILC2s at day 4 after
infection. WTmice were infected with 33 106 PFU of RSV strain 01/2-20 and harvested on days 0 to 10 after
infection. A, ELISA for IL-13 in whole-lung homogenate (right lung only). B, Representative IL-13 expression
measured by using flow cytometry in ILC2s (Lin2CD451CD251CD1271IL-131) and T cells (CD451CD31IL-
131) compared with isotype control staining at day 4 after infection. Numbers indicate the percentage of
T cells or ILC2s within the gated region. C, Total number of live cells. D, Percentage of live cells that are
ILCs. E, Total number of ILCs. F, MFI of side-scatter area in ILCs. G, Percentage of live cells that are IL-131
ILC2s. H, Total numbers of IL-131 ILC2s. I, MFI of IL-13 in IL-131 ILC2s measured at day 4 after infection.
Data are plotted as means 6 SEMs. For Fig 1, A, n 5 8 to 14 mice per group combined from 3 independent
experiments. For Fig 1, B, F, and I, data are representative of 3 independent experiments. For Fig 1, C-E and
G-H, n 5 15 mice per group combined from 3 independent experiments. **P < .01 and ***P < .001, 1-way
(Fig 1, C-F) or 2-way (Fig 1, A) ANOVA. n.s., Not significant. The dashed line is the limit of detection of the
assay.
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infection; however, it is a known stimulus of ILC2s in other
disease models and can be released from epithelial cells in a
fashion to IL-33 and IL-25. Moreover, previous studies have
shown that infections with RSV strains A2 and Line 19 provoke
TSLP expression in murine lungs, although these studies focused
on the effect of TSLP on dendritic cells and TH2 cells.
39,40
To determine whether TSLP is required for the RSV-induced
ILC2 response, we first measured the concentration of TSLP
using ELISA in the lungs of mock- and RSV-infected mice. We
identified a significant increase in the total concentration of TSLPin the lungs of RSV-infected mice compared with mock-infected
mice at 12 hours after infection (Fig 3,A). Measurements of TSLP
levels by using ELISA between 24 and 96 hours after infection
were all less than the limit of detection (data not shown).
Consistent with a role for TSLP in lung ILC2 activation during
RSV infection, we identified that lung ILC2s in naive mice
express TSLPR and are thus poised to respond directly to TSLP
(Fig 3, B). To determine the role of TSLP during RSV-induced
ILC2 activation, we assayed the total number of ILCs and
IL-131 ILC2s in TSLPR KO mice at day 4 after infection. Both
WT and TSLPR KO mice displayed a substantial inflammatory
FIG 2. RSV-stimulated ILC2 proliferation at day 4 after infection. WT mice
were infected with 3 3 106 PFU of RSV strain 01/2-20, and lungs were
harvested for flow cytometry at day 4 after infection. Cells were gated for
viable IL-131 ILC2s and analyzed for Ki67. A, Representative plots for Ki67
staining. Numbers indicate the percentage of Ki671 ILCs or Ki671IL-131
ILC2s within the gated region. B and C, Total number of Ki671 ILCs (Fig 2,
B) and Ki671IL-131 ILC2s (Fig 2, C). Data are plotted as means 6 SEMs.
N 5 13-14 mice per group combined from 2 independent experiments.
**P < .01, unpaired t test.
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TSLPR KO mice had significantly reduced numbers of total
ILCs compared with WT RSV-infected mice (Fig 3, D). Among
these ILCs, RSV-infected TSLPR KO mice had similar numbers
of IL-131 ILC2s compared with mock-infected TSLPR KO
mice and significantly reduced numbers of IL-131 ILC2s
compared with RSV-infected WT mice (Fig 3, E). TSLPR
expression was also upregulated on total ILCs after RSVinfection
(Fig 3, F) and was selectively enhanced on IL-52IL-131 ILC2s
(Fig 3, G). Similarly, TSLPR expression was upregulated on
Ki671 ILCs compared with Ki672 ILCs (see Fig E3, A, in this
article’s Online Repository at www.jacionline.org), and high
levels of expression were restricted to Ki671IL-52IL-131
ILC2s (see Fig E3, B).
To determine the plausibility of exogenously targeting TSLP
signaling during RSV infection, we tested the effect of a TSLP
neutralizing antibody (clone 28F12) on RSV-driven ILC2
induction (Fig 3, H). RSV-infected mice treated either 6 or
36 hours after infection with a single 200-mg dose of TSLP
neutralizing antibody had a trend for a decrease in the total
numbers of ILCs compared with those seen in RSV-infected
mice treated with isotype control antibody, but this was not
statistically significant (Fig 3, I). Importantly, there was astatistically significant decrease in the number of IL-131 ILC2s
in the groups receiving TSLP neutralizing antibody at either 6
or 36 hours after infection compared with RSV-infected mice
treated with isotype control antibody (Fig 3, J).
Consistent with these data, we found that treatment of mice
every 24 hours with dexamethasone beginning 24 hours before
infection decreased lung TSLP expression and the total number
of IL-131 ILC2s at day 4 after infection compared with
vehicle-treated mice, further highlighting the importance of
TSLP during RSV-induced ILC2 activation (see Fig E4 in this
article’s Online Repository at www.jacionline.org). Of note, dexa-
methasone was administered prophylactically in our model, a key
distinction from human trials of corticosteroids in which adminis-
tration has been after infection and demonstrated to be ineffective.
Collectively, these data strongly suggest a TSLP-dependent
mechanism for the induction of IL-13–producing ILC2s after
RSV infection that could be potentially exploited therapeutically.
IL-33 and IL-25 have been implicated as activators of ILC2s
during infectionwith other respiratory tract viruses,15-17,21 and RSV
strain Line 19 has been shown to induce transcription of IL-25.41 To
determine the importance of these cytokines during RSV infection,
we measured the whole-lung concentration of IL-33 and IL-25 pro-
tein by using ELISA after RSVinfection.We identified a significant
increase in lung IL-33protein levels inRSV-infectedmicecompared
with those in mock-infected mice at 12 hours after infection (see
Fig E5, A, in this article’s Online Repository at www.jacionline.
org). IL-25 levelswere less than the limit of detection, as determined
by using ELISA, across the first 96 hours after infection (data not
shown). To determine whether IL-33 was required for activating
ILC2s during RSV infection, we measured the total number of
IL-131 ILC2s in the lungs at day 4 after infection in WT and
IL-33 KO mice. BothWTand IL-33 KO mice showed a significant
inflammatory response to RSV, as measured by total lung
cell numbers, compared with those after mock infection (see
Fig E5, B). RSV infection induced a significant increase in numbers
of IL-131 ILC2s compared with those after mock infection in both
WTand IL-33KOmice, and therewasno statistically significant dif-
ference in the total number of IL-131 ILC2s between RSV-infected
WT and IL-33 KO mice (see Fig E5, C). However, there was a
significant decrease in the total lung concentration of IL-13 in the
RSV-infected IL-33 KO mice compared with RSV-infected WT
mice (Fig E5, D), highlighting an equivocal role for IL-33 during
RSV-induced ILC2 activation in our murine model of infection.TSLPR-deficient mice exhibited decreased lung
IL-13 levels, airway mucus, airway reactivity, and
weight loss without an effect on viral load after RSV
infection
To consider the efficacy of targeting TSLP for the attenuation of
ILC2 responses during RSV infection, we considered the effect of
TSLPRdeficiency onRSVdisease severity.Notably,RSV-infected
TSLPR KOmice had significantly decreased levels of whole-lung
IL-13 compared with RSV-infected WT mice at day 4 after
infection (Fig 4, A). TSLP neutralization also had a trend for a
decrease in IL-13 whole-lung concentrations at day 4 after infec-
tion, although this was not statistically significant (see Fig E6 in
this article’s Online Repository at www.jacionline.org). We next
sought to determine the physiologic effect of early RSV-induced
IL-13 onmucous cell metaplasia and airwaymucus accumulation.
To allow time for this early IL-13 to induce physiologic changes in
FIG 3. RSV-induced TSLP signaling is required for ILC2 activation. WT or TSLPR KOmice were infected with
33 106 PFU of RSV strain 01/2-20, and lungs were harvested for ELISA or flow cytometry. A, ELISA for TSLP
in the whole-lung homogenate. B, TSLPR expression determined by using flow cytometry in IL-131 ILC2s
from naive mice. C-E, Total number of live cells (Fig 3, C), ILCs (Fig 3, D), and IL-131 ILC2s (Fig 3, E) as
measured by using flow cytometry at day 4 after infection. F, MFI of TSLPR on ILCs from mock- and
RSV-infected mice. G, MFI of TSLPR on ILC subsets in RSV-infected mice. H, Protocol for in vivo
neutralization of TSLP. I.P., Intraperitoneal. I and J, Total number of ILCs (Fig 3, I) and IL-131 ILC2s
(Fig 3, J), as measured by using flow cytometry at day 4 after infection. Data are plotted as
means 6 SEMs. For Fig 3, A, n 5 5 to 10 mice per group combined from 2 independent experiments. For
Fig 3, B, data are representative of 2 independent experiments. For Fig 3, C-E, n 5 9-15 mice per group
combined from 3 independent experiments. For Fig 3, F and G, n 5 10 mice per group. For Fig 3, I and J,
n 5 9-10 mice per group combined from 2 independent experiments. *P < .05 and ***P < .001, unpaired
t test (Fig 3, F), 1-way ANOVA (Fig 3, C-E, G, I, and J), or 2-way ANOVA (Fig 3, A). n.s., Not significant.
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mock- and RSV-infected WT and TSLPR KO mice at day 6 after
infection. Importantly, at day 6 after infection, there remained a
significant increase in the total number of ILCs, as well as IL-
131 ILC2s, but not IL-51 ILC2s (see Fig E7, A-C, in this article’s
Online Repository at www.jacionline.org). Additionally, therewas
an increase in total numbers of CD31 T cells but no significant in-
crease in numbers of IL-51 or IL-131 T cells, although a trend for
an increase was seen with IL-131 T cells (see Fig E7,D-F). These
data suggest that ILC2s remain a major component of the type 2immune response at day 6 after infection. In mock-infected WT
and TSLPR KO mice, there was minimal or absent mucous cell
metaplasia (Fig 4, B). In RSV-infected WT mice we identified
moderate mucous cell metaplasia and significant airway
mucus accumulation with both intraluminal mucus strands and
overt mucous plugging. RSV-infected TSLPR KO mice also
exhibited moderate mucous cell metaplasia, but they had
no substantial intraluminal mucus accumulation. Collective
scoring of airways from multiple mice showed a significant
decrease in mucus severity scores in RSV-infected TSLPR
FIG 4. TSLPR deficiency attenuated RSV-induced IL-13 production, airway mucus accumulation, airway
reactivity, and weight loss without negative effects on viral load. WT or TSLPR KO mice were infected with
3 3 106 PFU of RSV strain 01/2-20. A, IL-13 levels measured by using ELISA from whole-lung homogenate
(right and left lung) at day 4 after infection. B, Representative PAS-stained sections of mucus-containing
airways in the lungs on day 6 after infection (320 magnification). The arrowhead denotes intraluminal
mucus plugging. C, Quantification of airway mucus from the experiment in Fig 4, B. Each dot represents
a combined airway mucus score for an individual mouse. D, Airway reactivity measured at baseline and
increasing doses of methacholine at day 6 after infection. I.V., Intravenous. E, Daily weight loss displayed
as a percentage of original body weight before infection. F, Lung viral titers determined at days 2, 4, and
6 after infection by using a plaque assay. For Fig 4, A, n 5 5-10 mice combined from 2 independent
experiments. For Fig 4, B and C, n 5 8-9 mice per group combined from 2 independent experiments. For
Fig 4, D, n 5 5-10 mice per group. For Fig 4, E, n 5 12-15 mice per group combined from 3 independent
experiments. For Fig 4, F, n 5 6-8 mice per group combined from 2 independent experiments. All data
are plotted as means 6 SEMs. *P < .05, **P < .01, and ***P < .001, 1-way (Fig 4, A and C) or 2-way (Fig 4,
D-F) ANOVA. n.s., Not significant. For Fig 4, D-F, statistical comparisons indicated are between the WT
RSV and TSLPR KO RSV groups. The dashed line is the limit of detection of the assay. BL, Baseline.
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Fig E8 in this article’s Online Repository at www.jacionline.org).
The primary difference between these groups of mice was related
to the amount of intraluminal obstructing mucus, which was never
observed in the RSV-infected TSLPR KO mice.To evaluate airway obstruction and reactivity, we performed a
methacholine challenge experiment at day 6 after infection on
mock- or RSV-infected WT and TSLPR KO mice. We saw a
significant increase in airway reactivity in the RSV-infected WT
group compared with the RSV-infected TSLPR KO mice, with
FIG 5. Pathogenic clinical isolates of RSV induce IL-131 ILC2s throughTSLP.WTmicewere infectedwithRSV
strains 12/11-19 (1.03 106 PFU) or 12/12-6 (9.03 105 PFU), treated with either 200 mg of isotype or anti-TSLP
antibody at 6 hours after infection, and harvested on day 4 or 6 after infection.A and B, Total numbers of ILCs
and IL-131 ILC2s in mice infected with RSV 12/11-19 (Fig 5, A) and RSV 12/12-6 (Fig 5, B) at day 4 after
infection.C,Whole-lung IL-13 levelsmeasured bymeans of ELISA (right and left lung) at day 4 after infection.
D, Representative PAS-stained sections of mucus-containing airways in the lungs on day 6 after infection
(320 magnification). The arrowhead denotes intraluminal airway mucus. E,Quantification of airway mucus
from the experiment in Fig 5,D. Eachdot represents a combined airwaymucus score for an individualmouse.
Data are plotted asmeans6SEMs. For Fig 5,A andB, n5 8-10mice per group combined from2 independent
experiments. For Fig 5,C, n5 10mice per group combined from 2 independent experiments. For Fig 5,D and
E, n5 5 mice per group. *P < .05, **P < .01, and ***P < .001, 1-way ANOVA.
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differences were observed between mock- and RSV-infected
TSLPR KO mice.
Within the first 4 days after infection, both RSV-infected WT
and TSLPRKOmice had significant weight loss relative to mock-
infected control mice. However, RSV-infected TSLPR KO mice
had significantly less weight loss compared with RSV-infected
WT mice (Fig 4, E). Next, we sought to determine whether
TSLPR deficiency altered viral load. We did not observe any
significant differences in viral load at days 2, 4, or 6 after RSV
infection between TSLPR KO and WT mice (Fig 4, F). Together,
these data suggest that the absence of TSLP signaling is unlikely
to exacerbate disease or increase viral load and implicate TSLP as
a potential therapeutic target for attenuating ILC2-associated
immunopathology during RSV infection.
Multiple pathogenic clinical isolates of RSV induce
IL-13–producing ILC2s through a TSLP-dependent
mechanism
To determine the generalizability of our results and their
clinical relevance to strains of RSV with known human patho-
genic potential, we evaluated the ability of 2 recently collected
clinical isolates of RSV to induce ILC and IL-131 ILC2 numbers
and the necessity of TSLP in this process. RSV strains 12/11-19
and 12/12-6 were both isolated in 2012 as part of the INSPIRE
study from 2 different patients who were hospitalized with severelower respiratory tract infection and bronchiolitis.28 Mice were
infected with 1.0 3 106 or 9.0 3 105 PFU of 12/11-19 or
12/12-6, respectively, and the number of ILCs and IL-131
ILC2s was determined at day 4 after infection. Consistent with
our results obtained with RSV strain 01/2-20, both 12/11-19
and 12/12-6 induced a significant expansion of total ILCs and
IL-131 ILC2s by day 4 after infection (Fig 5, A and B). Moreover,
anti-TSLP neutralizing antibody was able to significantly
attenuate the RSV-induced IL-131 ILC2 response for both
12/11-19 and 12/12-6 (Fig 5, A and B). Importantly, both of these
clinical isolates induced the accumulation of IL-13 in the
whole-lung homogenate at day 4 after infection and airwaymucus
at 6 after infection (Fig 5, C-E), although significant weight loss
was only observed with 12/11-19 (see Fig E9 in this article’s
Online Repository at www.jacionline.org). Collectively, these
data demonstrate that the TSLP-dependent activation of ILC2s
is a conserved feature among RSV strains with known human
pathogenic potential that have recently circulated in the human
population.DISCUSSION
The immunologic contributions to the pathophysiology of
severe RSV infection are incompletely understood. Our studies
implicate the recently described ILC2s as a key source of IL-13
during the early stages of RSV infection in a murine model. We
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ILC2s during RSV infection. Moreover, TSLPR-deficient mice
had reduced airway mucus, airway reactivity, and weight loss and
a similar viral load compared with WT mice, suggesting that
TSLP might be a potential therapeutic target for IL-13–driven
immunopathology associated with RSV. Finally, we identified
that multiple recently collected clinical isolates of RSV with
known human pathogenic potential induced IL-13–producing
ILC2s through a TSLP-dependent mechanism. Collectively, these
data demonstrate the importance of ILC2s and TSLP during the
early stages of RSV infection and are the first to link TSLP to the
activation of ILC2s during a viral respiratory tract infection.
TSLP is primarily produced by epithelial cells, especially those
in the lungs and gut, as well as keratinocytes in the skin.42,43 Lung
epithelial cells are the primary site of RSV infection in human
subjects and mice,9,27 suggesting a means by which TSLP can
be elaborated rapidly after infection. Interestingly, direct
treatment of purified lung ILCs with TSLP alone did not induce
cell proliferation or IL-5 and IL-13 cytokine production (data
not shown; all values were less than the limit of detection). It is
possible that TSLP is acting on non-ILCs to produce further
signals that activate ILC2s. However, our data demonstrating
that lung ILC2s express the TSLPR and that changes in TSLPR
expression are restricted to the ILC2 subset, which is increasing
in number, suggest that TSLP is likely having direct effects on
ILC2s. Previous studies have shown that TSLP acts synergisti-
cally with other stimuli, rather than individually, to potentiate
murine and human ILC2.44,45 Together, these data suggest that
an additional collaborative partner or partners might play a role
in conjunction with TSLP during the in vivo activation of ILC2s
after RSV infection.
IL-33 has been shown to be an important activator of ILC2s in
mouse models of allergic airway inflammation, influenza
infection, and rhinovirus infection.12,14,16,18,19,21,46,47 Interest-
ingly, we found similar numbers of IL-13–producing ILC2s after
RSV infection in IL-33–deficient mice, although there was a
statistically significant decrease in the total lung concentration
of IL-13 at day 4 after infection. These incongruous results could
be explained in the IL-33–deficient mice by potentially defective
functionality of ILC2s despite similar numbers as seen in WT
mice or different kinetics or localization of the ILC2 response.
Also, we cannot exclude additional sources of IL-13 in these
mice, including epithelial cells themselves,48 which could be
susceptible to IL-33 deficiency, leading to decreased total lung
IL-13 concentrations despite stable numbers of IL-13–producing
ILC2s. Age-variable effects of IL-33 on ILC2s in the mouse
model of RSV infection might also play a role.49
Furthermore, ILC2 activation in the neonatal mouse model of
rhinovirus infection requires IL-25.17 Additionally, RSV strain
Line 19 has been shown to induce IL-25 transcription in
mice.41 However, we did not detect this cytokine by using ELISA
after RSV infection with strain 01/2-20, suggesting it is less likely
to play a role in this model.
Beyond IL-33 and IL-25, additional proinflammatory
molecules, including cysteinyl leukotrienes (notably leukotriene
D4) and TNF family cytokines (notably TLA1) have recently been
identified as activators of ILC2s and might play a role, in
conjunction with TSLP, during RSV infection.50,51 Future studies
will be required to precisely define the network of cytokines
influencing ILC2 activation during RSV infection, although our
data strongly suggest a critical role for TSLP in this milieu.Importantly, the identification of TSLP as an activator of ILC2s
is distinct from other respiratory tract viruses. These data
highlight that different respiratory tract viruses induce ILC2s
through unique mechanisms. Determination of the precise stimuli
for ILC2s in each disease model will be necessary when
conceptualizing and developing therapeutics, specifically with
monotherapies targeting only IL-33, IL-25, or TSLP.
A recent phase I randomized controlled trial evaluated the
effectiveness of an anti-TSLP mAb, AMG 157, in reducing
disease severity in patients with mild allergic asthma.52 Patients
randomized to AMG 157 had reduced airway obstruction and
inflammation relative to patients receiving placebo after
aeroallergen challenge. Both airway obstruction and inflamma-
tion are associated with TH2 cytokines, including IL-13. Given
that RSV induces a TSLP-dependent, IL-13–producing ILC2
response in mice and that IL-13 promotes airway obstruction, it
is intriguing to consider the therapeutic potential of an
anti-TSLP mAb for treating severe RSV infection. Our studies
demonstrate that a neutralizing mAb targeting TSLP was capable
of reducing the number of IL-13–producing ILC2s in the lungs of
mice after RSV infection, providing a small-animal model proof
of concept for this therapeutic approach. Critically, it has been
demonstrated that RSV infection can stimulate the production
of TSLP in primary human airway epithelial cells, supporting
the translational significance of TSLP during RSV infection.39
In addition, TSLP has previously been shown to enhance the
CD41 TH2 compartment during the later stages of RSV
infection.39,40 The use of an anti-TSLP mAb might also have
the dual benefit of decreasing both ILC2 and CD41 TH2
contributions to immunopathology. Additional studies will be
required to further assess the feasibility of an anti-TSLP mAb
during severe RSV infection in human subjects.
Interestingly, neutralization of TSLP significantly attenuated
IL-131 ILC2 induction during RSV infection irrespective of
whether intervention occurred 6 or 36 hours after infection.
This was surprising given that the peak of TSLP in the lungs
occurred 12 hours after infection. One potential explanation for
these data is the continued production of TSLP in the lungs
beyond 12 hours after infection, which is physiologically
significant but less than the limit of detection of the ELISA.
Dynamic changes in TSLPR expression on ILC2s might play a
critical role in responsiveness to this submaximal TSLP.
Specifically, we identified that TSLPR is increased in expression
on ILCs after RSV infection and that the increased expression
clusters most significantly with proliferating Ki671IL-52IL-
131 ILC2s. Increased receptor expression in this subset might
allow for continued responsiveness to levels of TSLP that are
less than the limit of detection of our ELISA.
Furthermore, our data suggest a deficiency in TSLP signaling is
unlikely to affect viral load and might improve clinical illness as
measured by weight loss, all while attenuating IL-13–producing
ILC2s, whole-lung concentrations of IL-13, airway mucus
accumulation, and airway reactivity. Although the human
pathogenesis of RSV is multifaceted, inclusive of both viral and
host contributions, several lines of evidence suggest that
immunopathology and airway mucus hypersecretion promote
disease severity in infants.9,53 Importantly, we did not identify any
significant increase in viral load in TSLPR-deficient mice,
suggesting that the targeting of the TSLP axis is unlikely to
exacerbate virally associated disease metrics while still providing
relief to immunopathologic changes in the airways. It is relevant
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severity in mice, the direct implications of this murine
observation to prognosis or disease course in human subjects
remain unclear.
Viral respiratory tract infections, including RSV, are an
important cause of asthma exacerbations in both children and
adults.54 Atopic asthma is associated with increased levels of TH2
cytokines in the airways, including IL-4.55-57 Several studies
demonstrate that IL-4 enhances the capacity of human airway
epithelial cells to produce TSLP.58,59 Moreover, the combination
of IL-4 plus double-stranded RNA synergistically enhanced pro-
duction of TSLP from human airway epithelial cells.58 Together,
it is intriguing to consider whether a mechanism exists for RSV-
induced asthma exacerbation whereby pre-existing allergic
inflammation and IL-4 production can prime airway epithelial
cells to produce augmented levels of TSLP on infection with
RSV, leading to an exaggerated ILC2 response with increased
TH2 cytokine production. Consistent with this hypothesis, airway
epithelial cells isolated from asthmatic children express greater
levels of TSLP on in vitro RSV infection than airway epithelial
cells isolated from nonasthmatic children.39 Further studies will
be needed to determine whether such a mechanism exists and,
if so, to what degree it influences RSV-exacerbated asthma.
Our data demonstrate that ILC2s are an important source of IL-
13 during the early stages of RSV infection in a murine model.
This process required TSLP signaling, and the lack of TSLP
signaling did not negatively affect viral load but significantly
reduced disease severity, as measured by weight loss, airway
mucus accumulation, and airway reactivity. Additionally, infec-
tion of mice with 2 recent clinical isolates of RSV with known
human pathogenic potential similarly induced IL-13–producing
ILC2s through a TSLP-dependent mechanism. These studies
have significant and broad implications for the targeting of ILC2s
during primary RSV infection, potentially through neutralization
of TSLP, as well as during RSV-induced wheezing illnesses.
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Key messages
d RSV infection increased the number of IL-13–producing
ILC2s through TSLP signaling in a murine model of
RSV infection.
d Deficiency in TSLP signaling decreased lung IL-13 con-
centrations, attenuated airway mucus and reactivity, did
not enhance viral load, and partially protected against
RSV-induced weight loss.
d Multiple RSV strains isolated from patients hospitalized
with severe RSV-induced bronchiolitis were capable of
inducing IL-13–producing ILC2s through TSLP in a mu-
rine model.REFERENCES
1. Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric
hospitalizations, 1997 to 1999. Pediatr Infect Dis J 2002;21:629-32.
2. Reassessment of the indications for ribavirin therapy in respiratory syncytial virus
infections. American Academy of Pediatrics Committee on Infectious Diseases.
Pediatrics 1996;97:137-40.
3. Klassen TP, Sutcliffe T, Watters LK, Wells GA, Allen UD, Li MM.
Dexamethasone in salbutamol-treated inpatients with acute bronchiolitis: a
randomized, controlled trial. J Pediatr 1997;130:191-6.
4. Plint AC, Johnson DW, Patel H, Wiebe N, Correll R, Brant R, et al. Epinephrine
and dexamethasone in children with bronchiolitis. N Engl J Med 2009;360:
2079-89.
5. Corneli HM, Zorc JJ, Mahajan P, Shaw KN, Holubkov R, Reeves SD, et al.
A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis.
N Engl J Med 2007;357:331-9.
6. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial
virus monoclonal antibody, reduces hospitalization from respiratory syncytial
virus infection in high-risk infants. Pediatrics 1998;102:531-7.
7. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al.
Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial
virus in young children with hemodynamically significant congenital heart
disease. J Pediatr 2003;143:532-40.
8. Committee on Infectious Diseases and Bronchiolitis Guidelines Committee.
Updated guidance for palivizumab prophylaxis among infants and young children
at increased risk of hospitalization for respiratory syncytial virus infection.
Pediatrics 2014;134:e620-38.
9. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology
of fatal untreated human respiratory syncytial virus infection. Mod Pathol 2007;
20:108-19.
10. Cohn L, Homer RJ, Marinov A, Rankin J, Bottomly K. Induction of airway
mucus production By T helper 2 (Th2) cells: a critical role for interleukin 4 in
cell recruitment but not mucus production. J Exp Med 1997;186:1737-47.
11. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, et al. Pulmonary expres-
sion of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial
fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999;
103:779-88.
12. Halim TYF, Krauss RH, Sun AC, Takei F. Lung natural helper cells are a critical
source of Th2 cell-type cytokines in protease allergen-induced airway
inflammation. Immunity 2012;36:451-63.
13. Turner JE, Morrison PJ, Wilhelm C, Wilson M, Ahlfors H, Renauld JC, et al.
IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control
in helminth-induced lung inflammation. J Exp Med 2013;210:2951-65.
14. Barlow JL, Bellosi A, Hardman CS, Drynan LF, Wong SH, Cruickshank JP, et al.
Innate IL-13-producing nuocytes arise during allergic lung inflammation and
contribute to airways hyperreactivity. J Allergy Clin Immunol 2012;129:191-8,
e1-4.
15. Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CG, Doering TA,
et al. Innate lymphoid cells promote lung-tissue homeostasis after infection
with influenza virus. Nat Immunol 2011;12:1045-54.
16. Chang YJ, Kim HY, Albacker LA, Baumgarth N, McKenzie AN, Smith DE, et al.
Innate lymphoid cells mediate influenza-induced airway hyper-reactivity
independently of adaptive immunity. Nat Immunol 2011;12:631-8.
17. Hong JY, Bentley JK, Chung Y, Lei J, Steenrod JM, Chen Q, et al. Neonatal
rhinovirus induces mucous metaplasia and airways hyperresponsiveness through
IL-25 and type 2 innate lymphoid cells. J Allergy Clin Immunol 2014;134:
429-39.
18. Bartemes KR, Iijima K, Kobayashi T, Kephart GM, McKenzie AN, Kita H. IL-
33-responsive lineage- CD251 CD44(hi) lymphoid cells mediate innate type 2
immunity and allergic inflammation in the lungs. J Immunol 2012;188:1503-13.
19. Barlow JL, Peel S, Fox J, Panova V, Hardman CS, Camelo A, et al. IL-33 is more
potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate
lymphoid cells) and airway contraction. J Allergy Clin Immunol 2013;132:
933-41.
20. Doherty TA, Khorram N, Chang JE, Kim HK, Rosenthal P, Croft M, et al. STAT6
regulates natural helper cell proliferation during lung inflammation initiated by
Alternaria. Am J Physiol Lung Cell Mol Physiol 2012;303:L577-88.
21. Jackson DJ, Makrinioti H, Rana BM, Shamji BW, Trujillo-Torralbo MB, Footitt J,
et al. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma
exacerbations in vivo. Am J Respir Crit Care Med 2014;190:1373-82.
22. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes
represent a new innate effector leukocyte that mediates type-2 immunity. Nature
2010;464:1367-70.
J ALLERGY CLIN IMMUNOL
SEPTEMBER 2016
824 STIER ET AL23. Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, et al. Innate
production of T(H)2 cytokines by adipose tissue-associated c-Kit(1)Sca-1(1)
lymphoid cells. Nature 2010;463:540-4.
24. Price AE, Liang HE, Sullivan BM, Reinhardt RL, Eisley CJ, Erle DJ, et al.
Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc
Natl Acad Sci U S A 2010;107:11489-94.
25. Klein Wolterink RGJ, Kleinjan A, van Nimwegen M, Bergen I, de Bruijn M,
Levani Y, et al. Pulmonary innate lymphoid cells are major producers of IL-5
and IL-13 in murine models of allergic asthma. Eur J Immunol 2012;42:
1106-16.
26. Gorski SA, Hahn YS, Braciale TJ. Group 2 innate lymphoid cell production of
IL-5 is regulated by NKT cells during influenza virus infection. PLoS Pathog
2013;9:e1003615.
27. Stokes KL, Chi MH, Sakamoto K, Newcomb DC, Currier MG, Huckabee MM,
et al. Differential pathogenesis of respiratory syncytial virus clinical isolates in
BALB/c mice. J Virol 2011;85:5782-93.
28. Larkin EK, Gebretsadik T, Moore ML, Anderson LJ, Dupont WD, Chappell JD,
et al. Objectives, design and enrollment results from the Infant Susceptibility to
Pulmonary Infections and Asthma Following RSV Exposure Study (INSPIRE).
BMC Pulm Med 2015;15:45.
29. Graham BS, Perkins MD, Wright PF, Karzon DT. Primary respiratory syncytial
virus infection in mice. J Med Virol 1988;26:153-62.
30. Sokol CL, Barton GM, Farr AG, Medzhitov R. A mechanism for the initiation of
allergen-induced T helper type 2 responses. Nat Immunol 2008;9:310-8.
31. Mosconi I, Geuking MB, Zaiss MM, Massacand JC, Aschwanden C, Kwong
Chung CK, et al. Intestinal bacteria induce TSLP to promote mutualistic T-cell
responses. Mucosal Immunol 2013;6:1157-67.
32. Cahenzli J, K€oller Y, Wyss M, Geuking MB, McCoy KD. Intestinal microbial
diversity during early-life colonization shapes long-term IgE levels. Cell Host
Microbe 2013;14:559-70.
33. Dulek DE, Newcomb DC, Toki S, Goliniewska K, Cephus J, Reiss S, et al. STAT4
deficiency fails to induce lung Th2 or Th17 immunity following primary or
secondary respiratory syncytial virus (RSV) challenge but enhances the lung
RSV-specific CD81 T cell immune response to secondary challenge. J Virol
2014;88:9655-72.
34. Peebles RS, Sheller JR, Johnson JE, Mitchell DB, Graham BS. Respiratory syn-
cytial virus infection prolongs methacholine-induced airway hyperresponsiveness
in ovalbumin-sensitized mice. J Med Virol 1999;57:186-92.
35. Peebles RS, Sheller JR, Collins RD, Jarzecka AK, Mitchell DB, Parker RA, et al.
Respiratory syncytial virus infection does not increase allergen-induced type 2
cytokine production, yet increases airway hyperresponsiveness in mice. J Med
Virol 2001;63:178-88.
36. Tripp RA, Moore D, Anderson LJ. TH(1)- and TH(2)-TYPE cytokine expression
by activated t lymphocytes from the lung and spleen during the inflammatory
response to respiratory syncytial virus. Cytokine 2000;12:801-7.
37. Spits H, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate
lymphoid cells—a proposal for uniform nomenclature. Nat Rev Immunol 2013;
13:145-9.
38. Molofsky AB, Nussbaum JC, Liang HE, Van Dyken SJ, Cheng LE, Mohapatra A,
et al. Innate lymphoid type 2 cells sustain visceral adipose tissue eosinophils and
alternatively activated macrophages. J Exp Med 2013;210:535-49.
39. Lee HC, Headley MB, Loo YM, Berlin A, Gale M Jr, Debley JS, et al.
Thymic stromal lymphopoietin is induced by respiratory syncytial virus-
infected airway epithelial cells and promotes a type 2 response to infection.
J Allergy Clin Immunol 2012;130:1187-96.e5.
40. Han J, Dakhama A, Jia Y, Wang M, Zeng W, Takeda K, et al.
Responsiveness to respiratory syncytial virus in neonates is mediated through
thymic stromal lymphopoietin and OX40 ligand. J Allergy Clin Immunol 2012;
130:1175-86.e9.41. Petersen BC, Dolgachev V, Rasky A, Lukacs NW. IL-17E (IL-25) and IL-17RB
promote respiratory syncytial virus-induced pulmonary disease. J Leukoc Biol
2014;95:809-15.
42. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, et al. Human
epithelial cells trigger dendritic cell mediated allergic inflammation by producing
TSLP. Nat Immunol 2002;3:673-80.
43. Liu YJ, Soumelis V, Watanabe N, Ito T, Wang YH, Malefyt Rde W, et al. TSLP:
an epithelial cell cytokine that regulates T cell differentiation by conditioning
dendritic cell maturation. Annu Rev Immunol 2007;25:193-219.
44. Mj€osberg J, Bernink J, Golebski K, Karrich JJ, Peters CP, Blom B, et al. The
transcription factor GATA3 is essential for the function of human type 2 innate
lymphoid cells. Immunity 2012;37:649-59.
45. Mohapatra A, Van Dyken SJ, Schneider C, Nussbaum JC, Liang HE, Locksley
RM. Group 2 innate lymphoid cells utilize the IRF4-IL-9 module to coordinate
epithelial cell maintenance of lung homeostasis. Mucosal Immunol 2016;9:
275-86.
46. Kim HY, Chang YJ, Subramanian S, Lee HH, Albacker LA, Matangkasombut P,
et al. Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity
independently of adaptive immunity. J Allergy Clin Immunol 2012;129:216-27,
e1-6.
47. Hardman CS, Panova V, McKenzie AN. IL-33 citrine reporter mice reveal the
temporal and spatial expression of IL-33 during allergic lung inflammation.
Eur J Immunol 2013;43:488-98.
48. Shiraki Y, Ishibashi Y, Hiruma M, Nishikawa A, Ikeda S. Cytokine secretion
profiles of human keratinocytes during Trichophyton tonsurans and Arthroderma
benhamiae infections. J Med Microbiol 2006;55:1175-85.
49. Saravia J, You D, Shrestha B, Jaligama S, Siefker D, Lee GI, et al. Respiratory
syncytial virus disease is mediated by age-variable IL-33. PLoS Pathog 2015;
11:e1005217.
50. Doherty TA, Khorram N, Lund S, Mehta AK, Croft M, Broide DH. Lung type 2
innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates
TH2 cytokine production. J Allergy Clin Immunol 2013;132:205-13.
51. Yu X, Pappu R, Ramirez-Carrozzi V, Ota N, Caplazi P, Zhang J, et al. TNF
superfamily member TL1A elicits type 2 innate lymphoid cells at mucosal
barriers. Mucosal Immunol 2014;7:730-40.
52. Gauvreau GM, O’Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J, et al.
Effects of an anti-TSLP antibody on allergen-induced asthmatic responses.
N Engl J Med 2014;370:2102-10.
53. Collins PL, Graham BS. Viral and host factors in human respiratory syncytial
virus pathogenesis. J Virol 2008;82:2040-55.
54. Carroll KN, Hartert TV. The impact of respiratory viral infection on wheezing
illnesses and asthma exacerbations. Immunol Allergy Clin North Am 2008;28:
539-61, viii.
55. Wierenga EA, Snoek M, de Groot C, Chretien I, Bos JD, Jansen HM, et al.
Evidence for compartmentalization of functional subsets of CD21 T
lymphocytes in atopic patients. J Immunol 1990;144:4651-6.
56. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, et al.
Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic
asthma. N Engl J Med 1992;326:298-304.
57. Walker C, Bode E, Boer L, Hansel TT, Blaser K, Virchow JC Jr. Allergic and
nonallergic asthmatics have distinct patterns of T-cell activation and cytokine
production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis
1992;146:109-15.
58. Kato A, Favoreto S, Avila PC, Schleimer RP. TLR3- and Th2 cytokine-dependent
production of thymic stromal lymphopoietin in human airway epithelial cells.
J Immunol 2007;179:1080-7.
59. Kouzaki H, O’Grady SM, Lawrence CB, Kita H. Proteases induce production
of thymic stromal lymphopoietin by airway epithelial cells through protease-
activated receptor-2. J Immunol 2009;183:1427-34.
J ALLERGY CLIN IMMUNOL
VOLUME 138, NUMBER 3
STIER ET AL 824.e1METHODS
Virus and mice
Unless otherwise noted, all experiments were performed with RSV strain
01/2-20, which was isolated from a patient in 2001 in the Vanderbilt Vaccine
Clinic (Nashville, Tenn).E1 The 01/2-20 strain was selected because of its
recent isolation with limited in vitro passaging and its mucogenic potential.
Where indicated, we performed experiments using RSV strains 12/11-19
and 12/12-6, which were isolated in 2012 from hospitalized patients with
severe lower respiratory tract infection and bronchiolitis as part of the
INSPIRE study.E2 These viruses were propagated and titrated in HEp-2 cells,
as previously described.E3 Mock inoculum was prepared by collecting
cell-culture supernatants from lysed uninfected HEp-2 cells. UV inactivation
was performed by exposing the virus directly to a 30-W UV light for
40 minutes on ice. Female, 8- to 12-week-old IL-33 citrine reporter
(IL-33-deficient; IL-33 KO) mice, TSLPR-deficient (TSLPR KO) mice, or
WT BALB/c (WT) mice were used in compliance with the revised 1996
‘‘Guide for the care and use of laboratory animals’’ prepared by the
Committee on Care and Use of Laboratory Animals of the Institute of
Laboratory Animal Resources, National Research Council. IL-33 KO mice
and TSLPR KO mice were generated on or backcrossed to a BALB/c
background, as previously described.E4-E6 WT BALB/c mice were
purchased from the Jackson Laboratory. Mice were housed in microisolator
cages under specific pathogen-free conditions. For infection, mice were
anesthetized with a ketamine/xylazine solution and inoculated by means of
intranasal delivery with 3.0 3 106 PFU of RSV 01/2-20, 1.0 3 106 PFU of
RSV 12/11-19, 9.0 3 105 PFU of RSV 12/12-6, or an equal volume of
mock inoculum, as previously described.E3 Illness severity was measured
daily based on weight loss.
ELISA
Lungs were snap-frozen in liquid nitrogen at the time of harvest. Lungs
weremechanically disrupted by using 1mL of RIPA buffer (Sigma-Aldrich, St
Louis, Mo) with complete protease inhibitor (Roche Applied Science,
Penzberg, Germany) in a BeadBeater (BioSpec Products, Bartlesville,
Okla). Protein measurements were performed, according to the manufac-
turer’s instructions, by using ELISA kits from R&D Systems for IL-25
(DuoSet), IL-33 (DuoSet), TSLP (Quantikine), IL-4 (Quantikine), IL-5
(Quantikine), and IL-13 (Quantikine).
Flow cytometry
Right and left lungs were digested in RPMI media with 5% FBS, 1 mg/mL
collagenase, and 0.02 mg/mL DNase I for 60 minutes at 378C. A single-cell
suspension was generated by straining these digestions through a 70-mmfilter.
RBC lysis (BioLegend, San Diego, Calif) was performed, according to the
manufacturer’s instructions. Cells were restimulated with 10 ng/mL phorbol
12-myristate 13-acetate and 1 mmol/L ionomycin in the presence of 0.07%
monensin in Iscove modified Dulbecco medium media supplemented with
10% FBS, 0.01 mmol/L nonessential amino acids, penicillin/streptomycin,
and 1 mmol/L sodium pyruvate for 6 hours at 378C. Cells were stained with
LIVE/DEAD Blue (Life Technologies, Carlsbad, Calif) and combinations of
the following surface markers: CD45 (30-F11) and CD25 (PC61.5) from
eBioscience (San Diego, Calif); CD127 (SB/199) and CD3 (17A2) from
BioLegend; TSLPR (goat polyclonal) from R&D Systems; and a surface
marker cocktail containing CD5, CD45R (B220), CD11b, Gr-1 (Ly-6G/C),
7-4, and Ter-119 from Miltenyi Biotech (Bergisch Gladbach, Germany).
Cells were fixed/permeabilized and stained with combinations of the
following intracellular markers: IL-13 (eBio13A) and Ki67 (SolA15) from
eBioscience and IL-5 (TREK5) from BD Biosciences. All samples were
run on a BD LSR II Flow Cytometer and analyzed with FlowJo Software
Version 10.
Total ILCs were defined as Lin2CD451CD251CD1271 cells, where Lin
includes CD3, CD5, CD45R (B220), CD11b, Gr-1 (Ly-6G/C), 7-4, and
Ter-119. ILC2s were defined as ILCs that expressed IL-5, IL-13, or both.
T cells were defined as CD451CD31 cells. MFI was determined as the
geometric mean.In vivo TSLP neutralization
The monoclonal hybridoma cell line 28F12 was grown, and anti-TSLP
antibodies were purified by the Vanderbilt Antibody and Protein Resource.
The 28F12 hybridoma was developed by Dr Andrew Farr and obtained from
the Developmental Studies Hybridoma Bank. The Developmental Studies
Hybridoma Bank was created by the Eunice Kennedy Shriver National
Institute of Child Health andHumanDevelopment of the National Institutes of
Health andmaintained at the University of Iowa, Department of Biology, Iowa
City, Iowa. The 28F12mAb has demonstrated TSLP neutralizing activity with
efficacy for in vivo depletion.E7-E9 Purified rat IgG2ak isotype control mAb
was purchased from BioLegend (catalog no. 400544). At either 6 or 36 hours
after RSVinfection, mice received a single dose of 200mg of 28F12 or isotype
control antibody by means of intraperitoneal injection.
BAL and PAS staining
An intratracheal tube was inserted, and lungs were flushed with 0.8 mL of
physiologic saline solution. An aliquot of BAL fluid was taken to determine
total cells counts. For cell differentials, 0.1 mL of BAL fluid was spun onto
slides and stained with Diff-Quik kit (American Scientific Products, McGaw
Park, Ill) to visualize macrophages, lymphocytes, eosinophils, and neutro-
phils. For PAS staining, lungs were perfused with 13 PBS, inflated with 10%
neutral buffered formalin, and fixed in 20mL of 10%neutral buffered formalin
for 24 hours at room temperature. Lungs were then transferred to 70% ethanol,
paraffin embedded, sectioned (5 mm), and stained with PAS to visualize
mucus. Small- and medium-sized airways were scored for mucus by a trained
pathologist blinded to the experimental information using the following
scoring scheme as follows: 0, no PAS1 cells observed in cross-sections of
medium to small airways; 1, less than 10 PAS1 cells observed in cross-
sections of medium to small airways; 2, greater than 10 PAS1 cells observed
in cross-sections of medium to small airways; 3, greater than 10 PAS1 cells
observed in cross-sections of medium to small airways with mucous strands
observed in air spaces; or 4, greater than 10 PAS1 cells observed in
cross-sections of medium to small airways with mucous plugging of airways.
Corticosteroid treatment
Dexamethasone 21-phosphate disodium salt (Sigma-Aldrich) was prepared
by dissolving in PBS. Mice were treated with 2.5 mg/kg dexamethasone or an
equivalent volume of PBS vehicle administered by means of intraperitoneal
injection.Micewere treated 24 hours before infection, 1 hour before infection,
and every 24 hours after infection until mice were killed.
Airway reactivity
Airway reactivity was measured, as previously described.E10,E11 Briefly,
mice were anesthetized with an intraperitoneal injection of pentobarbital
sodium (85 mg/kg). A tracheostomy tube was inserted for ventilation. The
internal jugular vein was cannulated for intravenous delivery of acetyl-b-
methacholine. Mice were then placed in a whole-body plethysmography
chamber and mechanically ventilated. Precision glass microsyringes were
used to deliver increasing doses of acetyl-b-methacholine. Baseline airway
resistance measurements were collected, followed by measurements with
45, 137, 411, and 1233 mg/kg body weight of acetyl-b-methacholine. Peak
airway reactivity measurements for each dose were recorded.
Viral load
Mice were infected with 3.0 3 106 PFU of RSV 01/2-20, as described
above. On days 2, 4, and 6 after infection, lungs were collected, weighed,
and snap-frozen. Thawed lungs were resuspended in 1 mL of sterile MEM
media and homogenized through a BeadBeater. Lung homogenates were
serially diluted and used to infect subconfluent HEp-2 cells in 12-well plates
for 1 hour at room temperature while shaking. Cells were subsequently
overlaid with MEM supplemented with 10% FBS, penicillin G, streptomycin,
gentamicin, amphotericin B, and 0.75% methylcellulose and incubated at
378C. After 6 days, cells were fixed for 1 hour with 10% neutral buffered
formalin and stained with hematoxylin and eosin to visualize plaques.
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Data were analyzed with GraphPad Prism Version 5. Differences between
groups were evaluated by using the unpaired t test, 1-way ANOVA with the
Bonferroni posttest, or 2-way ANOVA with the Dunn multiple comparison
test, as appropriate. Measurements of less than the limit of detection were
assigned half of the value of the limit of detection to allow for statistical
analyses.REFERENCES
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FIG E1. Flow cytometric gating strategies. A, ILCs were defined as viable Lin2CD451CD251CD1271 cells.
ILC2s were defined as ILCs that were positive for either IL-5 or IL-13. B, T cells were defined as viable
CD451CD31 cells. FSC, Forward scatter; SSC, side scatter.
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FIG E2. RSV does not induce IL-5–producing ILC2s. WT mice were infected with 3 3 106 PFU of RSV strain
01/2-20 and harvested on days 0 to 10 after infection. A and B, ELISA for IL-4 (Fig E2, A) and IL-5 (Fig E2, B) in
whole-lung homogenate. C, Total number of live cells in the lungs at day 4 after infection. D, IL-51 ILC2s as a
percentage of viable cells as measured by using flow cytometry at day 4 after infection. E, Total number of
IL-51 ILC2s as measured by using flow cytometry at day 4 after infection. F,MFI of IL-5 staining in ILC2s as
measured by using flow cytometry at day 4 after infection. G, Percentage of cells in BAL fluid at day 4 after
infection. H, Total number of cells in BAL fluid at day 4 after infection. Data are plotted as means 6 SEMs.
For Fig E2, A and B, n5 8-14 mice per group combined from 2 independent experiments. For Fig E2, C-E,G,
andH, n5 10mice per group combined from 2 independent experiments. For Fig E2, F, n5 5mice per group
representative of 2 independent experiments. *P < .05, **P < .01, and ***P < .001, unpaired t test (Fig E2,
C-H) or 2-way ANOVA (Fig E2, A and B). n.s., Not significant. The dashed line is the limit of detection of
the assay. Eos, Eosinophils; Lym, lymphocytes; M4, macrophages; Neu, neutrophils.
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FIG E3. TSLPR expression in Ki671 and Ki672 subsets of ILCs at day 4 after RSV infection. WT mice were
infected with 3 3 106 PFU of RSV strain 01/2-20, and lungs were harvested for flow cytometry. A, MFI of
TSLPR expression determined by means of flow cytometry at day 4 after RSV infection stratified by Ki67
expression status. B, Subset analysis of ILCs stratified by Ki67 expression status in RSV-infected mice at
day 4 after infection. Data are plotted as means 6 SEMs. For Fig E3, A and B, n 5 5 mice per group.
**P < .01, and ***P < .001, 1-way ANOVA.
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FIG E4. Pretreatment of mice with dexamethasone (Dex) decreases TSLP expression and ILC2 activation.
WTmice were treated every 24 hours with 2.5 mg/kg dexamethasone beginning 1 day before infection until
harvest. Mice were infected on day 0 with 3 3 106 PFU of RSV strain 01/2-20, and lungs were harvested for
flow cytometry at day 4 after infection. A, Protocol for dexamethasone administration. B, ELISA for TSLP in
the whole-lung homogenate at 12 hours after infection. C, Total numbers of IL-131 ILC2s as measured by
using flow cytometry at day 4 after infection. Data are plotted as means 6 SEMs. For Fig E4, B, n 5 10
mice per group combined from 2 independent experiments. For Fig E4, C, n 5 5 mice per group
representative of 3 similar experiments. ***P < .001, 1-way ANOVA. n.s., Not significant.
J ALLERGY CLIN IMMUNOL
SEPTEMBER 2016
824.e6 STIER ET AL
FIG E5. RSV-induced IL-33 and ILC2s. WT or IL-33 KO mice were infected with 3 3 106 PFU of RSV strain
01/2-20, and lungs were harvested for ELISA or flow cytometry. A, ELISA for IL-33 in the whole-lung
homogenate. B, Total number of live cells in the lungs at day 4 after infection. C, Total numbers of IL-131
ILC2s as measured by using flow cytometry at day 4 after infection. D, ELISA for IL-13 in the whole-lung
homogenate (right and left lung) at day 4 after infection. Data are plotted as means 6 SEMs. For Fig E5,
A, n 5 5-10 mice per group combined from 2 independent experiments. For Fig E5, B and C, n 5 13-17
mice per group combined from 3 independent experiments. For Fig E5, D, n 5 4-5 mice per group from 1
independent experiment. *P < .05, **P < .01, and ***P < .001, 1-way (Fig E5, B and C) or 2-way (Fig E5, A)
ANOVA. n.s., Not significant.
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FIG E6. Lung IL-13 with TSLP neutralization. WT mice were infected with
3 3 106 PFU of RSV strain 01/2-20 and treated with 200 mg of anti-TSLP
antibody or isotype control at 6 hours after infection, and lungs were
harvested for ELISA at day 4 after infection. ELISA data are shown for
measurements of IL-13 levels in the whole-lung homogenate (right and
left lung). Data are plotted as means 6 SEMs. For Fig E6, A, n 5 15 mice
per group combined from 3 independent experiments. ***P < .001, 1-way
ANOVA.
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FIG E7. Analysis of ILCs and T cells at day 6 after infection. WT mice were infected with 3 3 106 PFU of RSV
strain 01/2-20 and harvested on day 6 after infection for flow cytometry. Total numbers of ILCs (A), IL-51
ILC2s (B), IL-131 ILC2s (C), T cells (D), IL-51 T cells (E), and IL-131 T cells (F) were determined. Data are
plotted as means 6 SEMs. For Fig E6, A-E, n 5 10 mice per group from 2 independent experiments.
*P < .05 and ***P < .001, unpaired t test. n.s., Not significant.
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FIG E8. Supplementary histopathologic sections from WT and TSLPR-
deficient mice at day 6 after infection. WT or TSLPR KO mice were infected
with 3 3 106 PFU of RSV strain 01/2-20. Additional representative
PAS-stained sections of mucus-containing airways in the lungs on day 6
after infection (320 magnification). The arrowhead denotes intraluminal
mucus plugging.
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FIG E9. RSV-induced weight loss with 2012 clinical isolates. WT mice were infected with RSV strains
12/11-19 (1.03 106 PFU;A) or 12/12-6 (9.03 105 PFU; B), andweight loss wasmeasured daily for 4 days. Data
are displayed as a percentage of initial body weight and represent means6 SEMs. For Fig E9, A-B, n5 8-10
mice per group from 2 independent experiments. *P < .05, 2-way ANOVA.
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